America में $142 Billion का सबसे बड़ा बदलाव — India के लिए Warning या Opportunity? #bull
$142 billion worth of drug sales will lose patent protection between 2026 and 2030. That is not a forecast — it is already written on the calendar. And most Indian investors are positioned on the wrong side of it.Global pharma is a two-sided trade. On one side sit the innovators — companies that discover new drugs, get a 20-year patent, and earn monopoly-level margins. On the other side sit the generic manufacturers, who wait for that patent to expire and then sell the same molecule cheap. Indian pharma companies are the best generic manufacturers in the world. But that is side two. Side one — the licence — is sold in America. In this video I break down what the patent cliff actually is, why JP Morgan expects large-cap pharma to beat the market in 2026, and most importantly, I hand you the BullTrack FIVE LENS MODEL — a simple 10-point scoring system that lets you judge any US stock in under 5 minutes, sitting in India, without a Bloomberg terminal.
Then we go live on screen and run the model on three real US pharma names — Eli Lilly (LLY), Moderna (MRNA) and Pfizer (PFE) — using Tickertape's US stocks portal. You will see exactly where each number comes from, exactly how the score is assigned, and exactly why a 6/10 stock can still rally while a 2/10 stock should be avoided at any valuation.
If you have only ever owned Indian pharma, this video will show you the half of the industry you have never looked at.
━━━━━━━━━━━━━━━━━━━━━━
⏱️ TIMESTAMPS
━━━━━━━━━━━━━━━━━━━━━━
0:00 — The $142 billion patent cliff
0:42 — The two sides of global pharma: innovator vs generic
1:18 — What we will cover today
1:51 — What is a patent cliff? (the chai stall analogy)
2:40 — Which business would YOU rather own?
3:02 — Where Indian pharma actually sits in this trade
3:17 — Why now? Force 1: cheapest valuations in years
3:52 — Force 2: the drug pricing overhang is gone
4:19 — Force 3: the patent cliff starts an M&A race
4:50 — The biggest mistake retail investors make
5:23 — The BullTrack FIVE LENS MODEL explained
5:56 — Lens 1: Growth Engine (is the business growing?)
6:26 — Lens 2: Margin Moat (does it have pricing power?)
7:02 — Lens 3: Earnings Quality (is the profit real?)
7:26 — Lens 4: Balance Sheet (who actually owns the company?)
7:45 — Lens 5: Capital Allocation (does cash come back to you?)
8:11 — LIVE DEMO: Tickertape US stock screener
8:58 — Case Study 1: Eli Lilly (LLY)
14:29 — LLY scores 6/10 — so now what?
14:42 — Growth vs quality: which one matters, and when
16:28 — The scoring rules: buy, watchlist, avoid
16:44 — Case Study 2: Moderna (2/10)
18:04 — Bonus case: Pfizer — great score, no growth
18:57 — Investing in US stocks from India (GIFT City, ₹100 minimum)
19:36 — Should you sell your Indian pharma stocks? 20:02 — The 5-line summary
━━━━━━━━━━━━━━━━━━━━━━
🔍 THE FIVE LENS MODEL — QUICK REFERENCE
━━━━━━━━━━━━━━━━━━━━━━
1 Growth: 5yr revenue
2 Moat: GP/Revenue
3 Quality: OCF/Net Income
4 Balance: Liab/Assets
5 Capital: FinCF/OCF
7+= buy | 4-6 = watchlist | Less than 4 = avoid
📌 RELATED SEARCHES THIS VIDEO ANSWERS
patent cliff 2026 explained | US pharma stocks 2026 | how to analyse US stocks from India | US stock screener India | Eli Lilly stock analysis | Moderna stock analysis 2026 | Pfizer stock analysis | invest in US stocks from India GIFT City | fundamental analysis model for beginners | global diversification for Indian investors | innovator vs generic pharma business model | JP Morgan pharma outlook 2026 | operating cash flow to net income ratio | gross margin analysis stocks | how to score a stock out of 10 | Indian pharma vs US pharma stocks | fractional investing US stocks India | Tickertape US stocks
═══════════════════════════════════════
📊 ABOUT TICKERTAPE (PAID PARTNERSHIP)
═══════════════════════════════════════
The entire live analysis in this video is done on Tickertape's US stocks portal:
Screen 7,000+ US stocks and ETFs from India
👉 Use code BULL26 for 1 month of Pro free — link in the top comment / description.
═══════════════════════════════════════
📊 BullTrack — When Markets Talk, We Translate
═══════════════════════════════════════
ABOUT BULLTRACK:
BullTrack is a SEBI Registered Research Analyst platform delivering institutional-grade market analysis for retail investors. We cover Indian equities, macroeconomics, derivatives, and global market transmission chains with original data-driven frameworks.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
⚠️ SEBI DISCLAIMER & COMPLIANCE NOTE
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
. This video is for educational and informational purposes only and does NOT constitute investment advice or a buy/sell recommendation. All data is from publicly available, named sources and has been independently verified.
#BullTrack #USStocks #PharmaStocks #PatentCliff #StockMarketIndia #Tickertape #GlobalInvesting #EliLilly #FundamentalAnalysis #StockAnalysis #InvestingForBeginners #GIFTCity #Moderna #Pfizer #ShareMarket #NiftyPharma Receive SMS online on sms24.me
TubeReader video aggregator is a website that collects and organizes online videos from the YouTube source. Video aggregation is done for different purposes, and TubeReader take different approaches to achieve their purpose.
Our try to collect videos of high quality or interest for visitors to view; the collection may be made by editors or may be based on community votes.
Another method is to base the collection on those videos most viewed, either at the aggregator site or at various popular video hosting sites.
TubeReader site exists to allow users to collect their own sets of videos, for personal use as well as for browsing and viewing by others; TubeReader can develop online communities around video sharing.
Our site allow users to create a personalized video playlist, for personal use as well as for browsing and viewing by others.
@YouTubeReaderBot allows you to subscribe to Youtube channels.
By using @YouTubeReaderBot Bot you agree with YouTube Terms of Service.
Use the @YouTubeReaderBot telegram bot to be the first to be notified when new videos are released on your favorite channels.
Look for new videos or channels and share them with your friends.
You can start using our bot from this video, subscribe now to America में $142 Billion का सबसे बड़ा बदलाव — India के लिए Warning या Opportunity? #bull
What is YouTube?
YouTube is a free video sharing website that makes it easy to watch online videos. You can even create and upload your own videos to share with others. Originally created in 2005, YouTube is now one of the most popular sites on the Web, with visitors watching around 6 billion hours of video every month.
